Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by microcaphobbyon Dec 17, 2021 1:54pm

226 Views

Post# 34241476

This is likely year end selling

It will see a january bounce. microcaps with under 100 mill market cap get sold off in this kind of market, unlelss there is instiitutional support-- of which this stock has none right now. Mull is a smart dude so owning this stock is a bet on him that he can increase value. I will give him another year. Cash cushion really helps.

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features